Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Gains from Sales and Divestitures (2019 - 2025)

Assembly Biosciences (ASMB) has 6 years of Gains from Sales and Divestitures data on record, last reported at $51872.0 in Q4 2024.

  • For Q4 2024, Gains from Sales and Divestitures rose 20.92% year-over-year to $51872.0; the TTM value through Dec 2024 reached $51872.0, up 20.92%, while the annual FY2024 figure was $51872.0, 20.92% up from the prior year.
  • Gains from Sales and Divestitures reached $51872.0 in Q4 2024 per ASMB's latest filing, up from $42898.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $347096.0 in Q4 2021 and bottomed at $42898.0 in Q4 2023.
  • Average Gains from Sales and Divestitures over 5 years is $164834.6, with a median of $143491.5 recorded in 2021.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 135.39% in 2020, then crashed 82.8% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $297133.0 in 2020, then grew by 16.82% to $347096.0 in 2021, then dropped by 28.15% to $249376.0 in 2022, then plummeted by 82.8% to $42898.0 in 2023, then increased by 20.92% to $51872.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $51872.0 in Q4 2024, $42898.0 in Q4 2023, and $249376.0 in Q4 2022.